Compare Stocks: RADX, ONCY, ATRA, and ANIX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.77 +0.4%	$3.30	$2.32 ▼ $5.46	$96.30M	0.51	346,323 shs	315,202 shs
ATRA Atara Biotherapeutics	$9.69 -0.2%	$8.93	$3.92 ▼ $19.15	$97.27M	0.1	46,720 shs	37,766 shs
ONCY Oncolytics Biotech	$0.77	$0.82	$0.73 ▼ $1.51	$98.18M	1.15	886,085 shs	491,478 shs
RADX Radiopharm Theranostics	$1.75 +1.1%	$2.83	$1.50 ▼ $16.25	$23.86M	1.53	67,978 shs	36,778 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	0.00%	+0.36%	-22.84%	-4.81%	-17.31%
ATRA Atara Biotherapeutics	0.00%	+3.30%	+3.30%	-3.77%	-16.39%
ONCY Oncolytics Biotech	0.00%	+3.29%	-3.95%	-19.79%	-42.96%
RADX Radiopharm Theranostics	0.00%	-11.67%	-23.62%	-60.70%	-75.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.77 +0.4%	$3.30	$2.32 ▼ $5.46	$96.30M	0.51	346,323 shs	315,202 shs
ATRA Atara Biotherapeutics	$9.69 -0.2%	$8.93	$3.92 ▼ $19.15	$97.27M	0.1	46,720 shs	37,766 shs
ONCY Oncolytics Biotech	$0.77	$0.82	$0.73 ▼ $1.51	$98.18M	1.15	886,085 shs	491,478 shs
RADX Radiopharm Theranostics	$1.75 +1.1%	$2.83	$1.50 ▼ $16.25	$23.86M	1.53	67,978 shs	36,778 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	0.00%	+0.36%	-22.84%	-4.81%	-17.31%
ATRA Atara Biotherapeutics	0.00%	+3.30%	+3.30%	-3.77%	-16.39%
ONCY Oncolytics Biotech	0.00%	+3.29%	-3.95%	-19.79%	-42.96%
RADX Radiopharm Theranostics	0.00%	-11.67%	-23.62%	-60.70%	-75.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	2.40	Hold	$10.00	261.01% Upside
ATRA Atara Biotherapeutics	2.50	Moderate Buy	$9.50	-1.96% Downside
ONCY Oncolytics Biotech	2.67	Moderate Buy	$5.00	549.35% Upside
RADX Radiopharm Theranostics	2.33	Hold	$11.00	528.93% Upside

Current Analyst Ratings Breakdown

Latest RADX, ONCY, ATRA, and ANIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/17/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/3/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/24/2026	ATRA Atara Biotherapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/19/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/19/2026	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
8/18/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/31/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	RADX Radiopharm Theranostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/15/2026	ATRA Atara Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	458.50	N/A	N/A	$0.38 per share	7.29
ATRA Atara Biotherapeutics	$120.77M	0.81	$4.87 per share	1.99	($5.34) per share	-1.81
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	($0.04) per share	N/A
RADX Radiopharm Theranostics	$1.88M	13.45	N/A	N/A	$1.28 per share	1.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$10.93M	-$0.32	N/A	N/A	N/A	N/A	-76.59%	-67.80%	N/A
ATRA Atara Biotherapeutics	$32.69M	-$1.18	N/A	7.02	N/A	-269.42%	-79.12%	-73.01%	10/29/2026 (Estimated)
ONCY Oncolytics Biotech	-$28.76M	-$0.34	N/A	N/A	N/A	N/A	-2,185.97%	-442.99%	11/11/2026 (Estimated)
RADX Radiopharm Theranostics	-$37.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest RADX, ONCY, ATRA, and ANIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q3 2026	ANIX Anixa Biosciences	-$0.0818	-$0.08	+$0.0018	-$0.08	N/A	N/A
8/12/2026	Q2 2026	ATRA Atara Biotherapeutics	-$0.3150	-$0.32	-$0.0050	-$0.32	$0.55 million	$0.63 million
8/12/2026	Q2 2026	ONCY Oncolytics Biotech	-$0.0538	-$0.08	-$0.0262	-$0.08	N/A	N/A
7/31/2026	Q4 2026	RADX Radiopharm Theranostics	N/A	-$0.81	N/A	-$0.8050	N/A	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
RADX Radiopharm Theranostics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.55	8.54
ATRA Atara Biotherapeutics	N/A	1.98	1.98
ONCY Oncolytics Biotech	N/A	1.35	1.35
RADX Radiopharm Theranostics	N/A	1.16	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
ATRA Atara Biotherapeutics	70.90%
ONCY Oncolytics Biotech	6.82%
RADX Radiopharm Theranostics	N/A

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	26.40%
ATRA Atara Biotherapeutics	41.20%
ONCY Oncolytics Biotech	0.10%
RADX Radiopharm Theranostics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	4	34.76 million	25.59 million	Optionable
ATRA Atara Biotherapeutics	330	10.04 million	5.90 million	No Data
ONCY Oncolytics Biotech	29	127.51 million	127.38 million	Not Optionable
RADX Radiopharm Theranostics	14	14.46 million	N/A	N/A

RADX, ONCY, ATRA, and ANIX Headlines

Recent News About These Companies

Radiopharm Theranostics (NASDAQ:RADX) Trading 1.1% Higher - Should You Buy?

September 19 at 1:41 AM | americanbankingnews.com

Radiopharm Selected For Late-Breaking Presentation Of Positive RAD101 Phase 2b Data; Stock Up

September 14, 2026 | rttnews.com

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro ...

September 14, 2026 | finance.yahoo.com

Radiopharm Theranostics Reports Positive Phase 1 Imaging Data For RAD 301 In Pancreatic Cancer

September 9, 2026 | rttnews.com

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

September 9, 2026 | globenewswire.com

Radiopharm Theranostics Ltd ADR (RADX)

September 1, 2026 | investing.com

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

August 26, 2026 | globenewswire.com

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

August 20, 2026 | globenewswire.com

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

August 17, 2026 | finance.yahoo.com

RADX: RAD101 Topline & FY:26 Cash Flows

August 3, 2026 | finance.yahoo.com

Radiopharm Dips on Securities Pact

July 25, 2026 | baystreet.ca

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

July 24, 2026 | globenewswire.com

Radiopharm Highlights Data Release

July 23, 2026 | baystreet.ca

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

July 22, 2026 | globenewswire.com

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

July 22, 2026 | globenewswire.com

Radiopharm Theranostics Ltd ADR RADX

July 16, 2026 | morningstar.comM

Radiopharm Theranostics Limited Sponsored ADR

May 14, 2026 | cnn.com

RADX: Fiscal 3Q:26 Cash Flow Report

May 13, 2026 | finance.yahoo.com

Radiopharm Theranostics Ltd. ADR

May 13, 2026 | barrons.com

Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs

April 28, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RADX, ONCY, ATRA, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.77 +0.01 (+0.36%)

As of 09/18/2026 04:00 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Atara Biotherapeutics NASDAQ:ATRA

$9.69 -0.02 (-0.21%)

As of 09/18/2026 04:00 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Oncolytics Biotech NASDAQ:ONCY

$0.77 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.78 +0.01 (+1.04%)

As of 09/18/2026 07:30 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Radiopharm Theranostics NASDAQ:RADX

$1.75 +0.02 (+1.10%)

Closing price 09/18/2026 03:56 PM Eastern

Extended Trading

$1.71 -0.04 (-2.23%)

As of 09/18/2026 07:30 PM Eastern

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RADX, ONCY, ATRA, and ANIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RADX, ONCY, ATRA, and ANIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RADX, ONCY, ATRA, and ANIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RADX, ONCY, ATRA, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Atara Biotherapeutics NASDAQ:ATRA

Oncolytics Biotech NASDAQ:ONCY

Radiopharm Theranostics NASDAQ:RADX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RADX, ONCY, ATRA, and ANIX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RADX, ONCY, ATRA, and ANIX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RADX, ONCY, ATRA, and ANIX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RADX, ONCY, ATRA, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Atara Biotherapeutics NASDAQ:ATRA

Oncolytics Biotech NASDAQ:ONCY

Radiopharm Theranostics NASDAQ:RADX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools